These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 32098522)

  • 1. Injectable combination therapies for the management of diabetes: an Indian perspective.
    Dutta D; Khandelwal D; Kalra S
    Expert Opin Drug Metab Toxicol; 2020 Mar; 16(3):209-216. PubMed ID: 32098522
    [No Abstract]   [Full Text] [Related]  

  • 2. Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature.
    Lisco G; De Tullio A; Guastamacchia E; Triggiani V
    Endocr Metab Immune Disord Drug Targets; 2021; 21(4):626-646. PubMed ID: 32628602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis.
    Castellana M; Cignarelli A; Brescia F; Laviola L; Giorgino F
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3082. PubMed ID: 30270567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review.
    Cimmaruta D; Maiorino MI; Scavone C; Sportiello L; Rossi F; Giugliano D; Esposito K; Capuano A
    Expert Opin Drug Saf; 2016 Dec; 15(sup2):77-83. PubMed ID: 27875915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes.
    Molina Vega M; Muñoz-Garach A; Tinahones FJ
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):207-217. PubMed ID: 29260924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of intensification therapies in Danes with Type 2 diabetes who use basal insulin: a population-based study.
    Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabet Med; 2017 Feb; 34(2):213-222. PubMed ID: 27279380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?
    Darmon P; Raccah D
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S21-6S27. PubMed ID: 26774016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
    Wright EE; Aroda VR
    Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy.
    Goldenberg RM; Berard L
    Curr Med Res Opin; 2018 Jan; 34(1):1-10. PubMed ID: 28836861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin.
    Alexopoulos AS; Buse JB
    Metabolism; 2019 Sep; 98():104-111. PubMed ID: 31255662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials.
    Maiorino MI; Chiodini P; Bellastella G; Scappaticcio L; Longo M; Giugliano D; Esposito K
    Diabetes Res Clin Pract; 2019 Aug; 154():101-115. PubMed ID: 31238059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes injectable therapy: type 2 diabetes management in Danish practice.
    Sterzi D; Auziere S; Jensen MM; Lopes S
    Curr Med Res Opin; 2017 Dec; 33(12):2211-2216. PubMed ID: 28875722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When should fixed ratio basal insulin/glucagon-like peptide-1 receptor agonists combination products be considered?
    David J; Fonseca V
    J Diabetes Complications; 2019 Dec; 33(12):107473. PubMed ID: 31668591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin dose adjustments with add-on glucagon-like peptide-1 receptor (GLP-1R) agonists in clinical practice.
    Artigas CF; Stokes V; Tan GD; Theodorakis MJ
    Expert Opin Pharmacother; 2015; 16(10):1417-21. PubMed ID: 26077113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'For me, it didn't seem as drastic a step as being controlled by insulin': A qualitative investigation of expectations and experiences of non-insulin injectable therapy among adults with type 2 diabetes.
    Holmes-Truscott E; Schipp J; Dunning T; Furler J; Hagger V; Holloway EE; Manski-Nankervis JA; Shaw JE; Skinner T; Speight J
    Diabet Med; 2022 Feb; 39(2):e14681. PubMed ID: 34465005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus.
    Forst T
    Expert Opin Pharmacother; 2016 Aug; 17(12):1703-8. PubMed ID: 27341040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs.
    Rodbard HW
    Diabetes Technol Ther; 2018 Jun; 20(S2):S233-S241. PubMed ID: 29870275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semaglutide (Ozempic)--another injectable GLP-1 receptor agonist for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Jan; 60(1539):19-21. PubMed ID: 29364197
    [No Abstract]   [Full Text] [Related]  

  • 20. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
    Meece J
    Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.